Details

Autor(en) / Beteiligte

• Epperla, Narendranath
• Ahn, Kwang W
• Litovich, Carlos
• Ahmed, Sairah
• Battiwalla, Minoo
• Cohen, Jonathon B
• Dahi, Parastoo
• Farhadfar, Nosha
• Farooq, Umar
• Freytes, Cesar O
• Ghosh, Nilanjan
• Haverkos, Bradley
• Herrera, Alex
• Hertzberg, Mark
• Hildebrandt, Gerhard
• Inwards, David
• Kharfan-Dabaja, Mohamed A
• Khimani, Farhad
• Lazarus, Hillard
• Lazaryan, Aleksandr
• Lekakis, Lazaros
• Murthy, Hemant
• Nathan, Sunita
• Nishihori, Taiga
• Pawarode, Attaphol
• Prestidge, Tim
• Ramakrishnan, Praveen
• Rezvani, Andrew R
• Romee, Rizwan
• Shah, Nirav N
• Sureda, Ana
• Fenske, Timothy S
• Hamadani, Mehdi

Titel

Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis

Ist Teil von

• Journal of hematology and oncology, 2019-01, Vol.12 (1), p.6-6, Article 6

Ort / Verlag

England: BioMed Central Ltd

Erscheinungsjahr

2019

Quelle

MEDLINE

Beschreibungen/Notizen

• There is a paucity of data on the role of allogeneic hematopoietic cell transplantation (allo-HCT) in patients with angioimmunoblastic T-cell lymphoma (AITL). Using the CIBMTR registry, we report here the outcomes of AITL patients undergoing an allo-HCT. We evaluated 249 adult AITL patients who received their first allo-HCT during 2000-2016. The median patient age was 56 years (range = 21-77). Majority of the patients were Caucasians (86%), with a male predominance (60%). Graft-versus-host disease (GVHD) prophylaxis was predominantly calcineurin inhibitor-based approaches while the most common graft source was peripheral blood (97%). Median follow-up of survivors was 49 months (range = 4-170 months). The cumulative incidence of grade 2-4 and grade 3-4 acute GVHD at day 180 were 36% (95% CI = 30-42) and 12 (95% CI = 8-17), respectively. The cumulative incidence of chronic GVHD at 1 year was 49% (95%CI 43-56). The 1-year non-relapse mortality (NRM) was 19% (95% CI = 14-24), while the 4-year relapse/progression, progression-free survival (PFS), and overall survival (OS) were 21% (95% CI = 16-27), 49% (95% CI = 42-56), and 56% (95% CI = 49-63), respectively. On multivariate analysis, chemoresistant status at the time of allo-HCT was associated with a significantly higher risk for therapy failure (inverse of PFS) (RR = 1.73 95% CI = 1.08-2.77), while KPS < 90% was associated with a significantly higher risk of mortality (inverse of OS) (RR = 3.46 95% CI = 1.75-6.87). Our analysis shows that allo-HCT provides durable disease control even in AITL patients who failed a prior auto-HCT and in those subjects with refractory disease at the time of allografting.